Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elagolix for Cardiovascular Risk in Endometriosis
NCT03746535Phase 1Completed
- Sponsor
- Yale University
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elagolix in endometriosis (2 arms), sponsored by Yale University. Primary endpoints: Flow Mediated Vasodilation at 1 month, Microdialysis Perfusions of Acetylcholine ED50 at 1 month and 3 more. Started Jul 2022; status: completed.
02
Drugs
elagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03746535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746535.